Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellsource Co Ltd (4880)
The Cellsource share price today is 340.0, view TYO 4880 stock exchange data. Track the latest Cellsource share price with real-time updates on 4880 stock performance including market cap, day range, 52-week range and dividend yield. Access 4880 charts, earnings dates and analyst estimates to support your investment decisions.
Tokyo
Currency in JPY
340.0
+3.0(+0.89%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
335.0
343.0
52 wk Range
294.0
635.0
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
335.0343.0
52 wk Range
294.0635.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.40%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.40%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4880 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Cellsource Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Cellsource Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Cellsource Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Earnings
Latest Release
10-06-2026
EPS / Forecast
1.89 / --
Revenue / Forecast
915M / 850M
Compare 4880 to Peers and Sector
Metrics to compare | 4880 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4880PeersSector | |
|---|---|---|---|---|
P/E Ratio | 97.3x | 15.4x | −0.4x | |
PEG Ratio | - | −0.30 | 0.00 | |
Price/Book | 1.1x | 1.5x | 2.6x | |
Price / LTM Sales | 1.9x | 1.3x | 3.1x | |
Upside (Analyst Target) | 158.1% | 0.5% | 49.3% | |
Fair Value Upside | Unlock | 17.2% | 6.7% | Unlock |
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cellsource (4880) Share Price Today?
The Cellsource share price today is 340.0.
What is the current Cellsource (4880) share price and day range?
As of 25-08-2026, the Cellsource share price is 340.0, with a previous close of 337.0. The share price has ranged from 335.0 to 343.0 today, while the 52-week range spans from 294.0 to 635.0.
What Is the Cellsource Market Cap?
As of today, Cellsource market cap is 6.69B.
Does Cellsource Pay Dividends? What's The Current Dividend Yield?
The Cellsource dividend yield is 1.4%.
What Is Cellsource's Earnings Per Share (TTM)?
The Cellsource EPS (TTM) is 3.5.
When Is the Next Cellsource Earnings Date?
Cellsource will release its next earnings report on 08-09-2026.
From a Technical Analysis Perspective, Is 4880 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Cellsource Trade On?
Cellsource is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for Cellsource?
The stock symbol for Cellsource is "4880."
How Many Times Has Cellsource Stock Split?
Cellsource has split 2 times.
How Many Employees Does Cellsource Have?
Cellsource has 148 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.